Rosetta Genomics, a developer and provider of microRNA-based molecular diagnostics, announced it has entered into definitive agreements with investors to purchase an aggregate of 570,755 ordinary shares at a price of $11.50 per share in a registered direct offering. Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes. Founded in 2000, the company is headquartered in Rehovot, Israel, with labs in Philadelphia.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Clean Energy Firm Completes Solar Project In North, South Israel
October 15, 2024
Cannabis Therapy Firm: CBD Jab Reduces Pain In Arthritic Dogs
October 15, 2024
US Government Funding Development Of Israeli Ebola Treatment
October 14, 2024
Security Firm Wins Prison Service Contract For Electronic Monitoring
October 14, 2024
Facebook comments